Approval for Roche’s cobas proⓇ integrated solutions

The FDA has approved Roche Diagnostics’ new generation of Serum Work Area laboratory solutions, cobas proⓇ integrated solutions, facilitating laboratories to run tests faster on less equipment, automate manual tasks and deliver results more quickly to aid in treatment decisions. It means around 2,200 tests can be performed every hour with three modules working in parallel and synchronized to improve efficiency. In terms of speed, the cobas pro integrated solutions requires around 3¼ hours less operating time for a daily routine workload compared with cobas 6000, while 93% of Roche Immunoassays have reaction times of 18 minutes or less.
Chief Executive Officer of Roche Diagnostics, Thomas Schinecker, said: “We are excited about the accelerated FDA clearance of the cobas pro integrated solutions, our new generation of Serum Work Area solutions inspired by our mission to help improve speed and reliability of treatment decisions for patients and their families. Reliable, fast and sustainable diagnostic solutions are vital for optimal clinical care delivery for patients, and a key element in the evolution of general healthcare quality.”